MedPath
NMPA Approval

Rezivertinib Mesylate Capsules

国药准字H20240017

May 15, 2024

Drug Information

甲磺酸瑞齐替尼胶囊

瑞必达

胶囊剂

30mg(按C₂₇H₃₀N₆O₃计)

化学药品

May 15, 2024

Company Information

Applicant Company

中国(上海)自由贸易试验区蔡伦路780号5楼H座

Manufacturing Company

中国(上海)自由贸易试验区意威路31弄4号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

甲磺酸瑞齐替尼胶囊 - NMPA 批准文号 | MedPath